Literature DB >> 4424666

Kinetics of salicylate elimination by anephric patients.

D T Lowenthal, W A Briggs, G Levy.   

Abstract

The objectives of this research were to determine the kinetics of salicylate elimination in anephric patients and particularly to establish if these patients form the major metabolite of salicylic acid, salicyluric acid, at a normal rate. This investigation was initiated because of conflicting reports concerning the contribution of the kidneys to the formation of salicyluric acid in man. Six patients, 20-44 yr old, three of whom were anatomically anephric while the other three were physiologically anephric, received an intravenous injection of 500 mg salicylic acid (as sodium salicylate)/1.73 m(2) body surface area on an interdialysis day. Serial blood samples were obtained for 12 or 16 h after injection and the plasma was assayed for salicylic acid, salicyluric acid, total protein, albumin, and creatinine. Detailed pharmacokinetic analysis based on an open, two-compartment linear model revealed no significant differences in apparent volume of distribution and apparent first-order distribution and elimination rate constants between the anephric patients and normal adult subjects. An estimate of salicyluric acid formation rate by the anephric patients, based on the initial rate of increase of salicylurate concentrations in plasma, indicates that the metabolite is formed at a normal rate. These results suggest that the kidneys do not contribute significantly to the formation of salicyluric acid from salicylic acid in man.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4424666      PMCID: PMC301669          DOI: 10.1172/JCI107865

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Decreased drug binding by serum albumin during renal failure.

Authors:  D S Campion
Journal:  Toxicol Appl Pharmacol       Date:  1973-07       Impact factor: 4.219

2.  Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.

Authors:  G Levy; T Tsuchiya; L P Amsel
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

3.  Biotransformation of salicylic acid to its acyl and phenolic glucuronides in man.

Authors:  T Tsuchiya; G Levy
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

4.  Renal contribution to overall metabolism of drugs. IV. Biotransformation of salicylic acid to salicyluric acid in man.

Authors:  B von Lehmann; S H Wan; S Riegelman; C Becker
Journal:  J Pharm Sci       Date:  1973-09       Impact factor: 3.534

5.  Salicylate accumulation kinetics in man.

Authors:  G Levy; T Tsuchiya
Journal:  N Engl J Med       Date:  1972-08-31       Impact factor: 91.245

6.  Capacity-limited salicylurate formation during prolonged administration of aspirin to healthy human subjects.

Authors:  G Levy; A W Vogel; L P Amsel
Journal:  J Pharm Sci       Date:  1969-04       Impact factor: 3.534

7.  Kinetics of salicyluric acid elimination in man.

Authors:  G Levy; L P Amsel; H C Elliott
Journal:  J Pharm Sci       Date:  1969-07       Impact factor: 3.534

8.  Some aspects of salicylate distribution and metabolism in man.

Authors:  L Hollister; G Levy
Journal:  J Pharm Sci       Date:  1965-08       Impact factor: 3.534

9.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

10.  Comparative pharmacokinetics of salicylate elimination in man and rats.

Authors:  E Nelson; M Hanano; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1966-07       Impact factor: 4.030

View more
  15 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 3.  Drug prescribing in renal failure.

Authors:  W M Bennett
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

4.  Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.

Authors:  I Odar-Cederlof
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

5.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 6.  The binding of drugs to plasma proteins from patients with poor renal function.

Authors:  M M Reidenberg
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 7.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

8.  Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.

Authors:  K J Berg
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

Review 9.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

Review 10.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.